The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Post hoc analysis of prior allo-HSCT conditioning regimens used following blinatumomab or chemotherapy in childhood B-ALL
|
Blinatumomab, a bispecific T-cell engager, was studied as part of a phase III trial (NCT02393859), which demonstrated an improvement in EFS and OS with blinatumomab vs SoC chemotherapy administered as third consolidation course in children with high-risk first-relapse B-ALL undergoing allo-HSCT. A post hoc analysis of this trial published in Haematologica by Peters et al.1 assessed outcomes based on the type of conditioning regimen patients received (TBI or chemo-conditioning) prior to allo-HSCT. |
| Key learnings |
|
For the 90 evaluable patients, post-transplant relapse occurred in 29% of patients who received blinatumomab compared with 62% of those who were treated with chemotherapy (irrespective of conditioning regimen). |
|
The estimated EFS at 36- and 48-months post-transplant for patients treated with blinatumomab were 63.8% and 60.2%, respectively, compared with 35.5% at both time points with SoC chemotherapy, regardless of the type of conditioning. |
|
Among patients treated with blinatumomab, EFS did not significantly differ between those who underwent TBI and those who received chemo-conditioning. |
|
Overall, pretransplant treatment with blinatumomab vs SoC chemotherapy was correlated with a statistically significant better OS based on a multivariate Cox regression model (HR, 0.33; 95% CI, 0.15–0.72; p = 0.005). |
|
The 2-year estimated OS was numerically higher in patients treated with blinatumomab who underwent TBI conditioning compared with in those who received chemo-conditioning (86.5% and 75.2%, respectively). |
|
This analysis demonstrated that children with high-risk first-relapse B-ALL who received blinatumomab as their third consolidation course before allo-HSCT had improved OS and EFS post allo-HSCT compared with those treated with SoC chemotherapy, regardless of whether they received TBI or chemo-conditioning. |
|
Further prospective studies are needed to evaluate the impact of substituting TBI for chemo-conditioning in various patient populations receiving blinatumomab before transplantation. |
Abbreviations: Allo-HSCT, allogenic hematopoietic stem cell transplant; B-ALL, B-cell acute lymphoblastic leukemia; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; SoC, standard of care; TBI, total body irradiation.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
